China Market Regulation Bureau Issued a 44,022,600 yuan antitrust fine to a Pharmaceutical Company

2021/04/07

 

On April 2, China Tianjin Tianyao Pharmaceutical Co., Ltd. issued an announcement stating that the Tianjin Administration for Market Regulation plans to impose administrative penalties on suspected of reaching a monopoly agreement for raw material of fluocinolone acetoacetate, with fines as high as 44,022,600 yuan.
 
In recent years, monopolies have frequently occurred in drug’s raw materials, which has become one of the critical areas for law enforcement by market regulation bureaus.